immune system
• upon in vivo injection of TLR7 and TLR9 agonists, mice fail to produce type I interferons
• total splenocytes, total marrow, spleen plasmacytoid dendritic cells, B cells, and neutrophils cells fail to produce either IFN-beta or IL-6 upon TLR7/9 stimulation but respond normally to TLR4 stimulation
• however, injection of TLR4 agonist LPS results in no differences compared to wild-type mice and bone-marrow derived macrophages and dendritic cells show little to modest differences upon TLR stimulation
• stimulation of Flt3L-derived plasmacytoid dendritic cells with agonists for other innate immune receptors such as TLR3 (polyI:C), TLR4 (LPS), cGAS (ISD), and RIG-1 (5pdsRNA), shows no defects in IL-6 cytokine production
|
• mice and total splenocytes, total marrow, spleen plasmacytoid dendritic cells, B cells, and neutrophils cells lack responses to TLR7/9 stimulation
|
• mice treated with imiquimod or pristane show no signs of systemic lupus erythematosus (SLE) phenotypes, indicating that mice are resistant to SLE development
• however, mice show no homeostatic differences in immune cell subsets within B cells, T cells, and myeloid cells under normal conditions
|
homeostasis/metabolism
• upon in vivo injection of TLR7 and TLR9 agonists, mice fail to produce type I interferons
• total splenocytes, total marrow, spleen plasmacytoid dendritic cells, B cells, and neutrophils cells fail to produce either IFN-beta or IL-6 upon TLR7/9 stimulation but respond normally to TLR4 stimulation
• however, injection of TLR4 agonist LPS results in no differences compared to wild-type mice and bone-marrow derived macrophages and dendritic cells show little to modest differences upon TLR stimulation
• stimulation of Flt3L-derived plasmacytoid dendritic cells with agonists for other innate immune receptors such as TLR3 (polyI:C), TLR4 (LPS), cGAS (ISD), and RIG-1 (5pdsRNA), shows no defects in IL-6 cytokine production
|